TY  - JOUR
AU  - Dendle, C
AU  - Gilbertson, M
AU  - Spelman, T
AU  - Stuart, RL
AU  - Korman, TM
AU  - Thursky, K
AU  - Opat, S
AU  - McQuilten, Z
Y2  - 2021/02/04
Y1  - 2017/06/30
SN  - 2045-2322
UR  - http://hdl.handle.net/11343/259603
AB  - To identify risk factors for infection in patients with diffuse large B cell lymphoma (DLBCL) undergoing rituximab, cyclophosphamide, vincristine, adriamycin and prednisolone (R-CHOP) treatment. All patients with DLBCL who received R-CHOP from 2004-2014 in a tertiary Australian hospital were identified and information collected from hospital admission data, laboratory results and medical record review. Infection was defined as hospitalisation with an ICD-10-AM diagnostic code for infection. Risk factors for infection and association between infection and survival were modelled using Cox proportional hazards regression. Over the 10-year period there were 325 patients; 191 (58.8%) males, median age 66 years. 206 (63.4%) patients experienced ≥1 infection. Independent predictors of infection were Charlson comorbidity index score (hazard ratio [HR] 3.60, p = 0.002), Eastern Cooperative Oncology Group (ECOG) performance status (HR 2.09 p = <0.001) and neutropenia (HR 2.46, p = <0.001). 99 (31%) patients died. Infection was an independent predictor of survival (HR 3.27, p = <0.001, as were age (HR 2.49, p = 0.001), Charlson comorbidity index (HR 4.34, p = <0.001), ECOG performance status (HR 4.33, p = 0.045) and neutropenia (HR 1.95, p = 0.047). Infections are common and infection itself is an independent predictor of survival. Patients at highest risk of infection and death are those with multiple comorbidities, poor performance status and neutropenia.
LA  - English
PB  - NATURE PUBLISHING GROUP
T1  - Infection is an Independent Predictor of Death in Diffuse Large B Cell Lymphoma
DO  - 10.1038/s41598-017-04495-x
IS  - Scientific Reports
VL  - 7
IS  - 1
L1  - /bitstream/handle/11343/259603/PMC5493675.pdf?sequence=1&isAllowed=y
ER  -